The B-ALL patients who showed CD25+/CD123+ expression was categorized as group 1, while those who showed single-positive expression (CD25+/CD123− or CD25−/CD123+) and double-negative expression (CD25−/CD123−) were categorized as group 2. This evidence concerns the gene IL3RA and acute lymphoblastic leukemia.